The diseases hepatitis B (HBV) and C (HCV) remain a significant health threat worldwide, causing approximately 1.3 million deaths each year.
Cardurion touts Phase 2 data for PDE9 inhibitor in heart failure, plans for two more trials
Cardurion Pharmaceuticals touted positive data for its heart failure drug and announced plans to pursue two more trials, three years after the Massachusetts biotech scored